The global cardiac biomarkers market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cardiovascular diseases and rising demand for cardiac biomarkers in emerging economies such as China and India. The global cardiac biomarkers market is segmented on the basis of type, application, and region. On the basis of type, it is classified into troponin, CMBs (cardiac myoglobin), natriuretic peptides BNP (brain natriuretic peptide) and NproBNP (N-terminal pro-B-type natriuretic peptide), myoglobin. On the basis of application, it includes acute coronary syndrome (ACS), myocardial infarction (MI), congestive heart failure (CHF). On the basis of region, it includes North America, Latin America, Europe Asia Pacific Middle East & Africa). Cardiac biomarkers are used to diagnose and monitor heart disease. The global cardiac biomarkers market is expected to grow at a CAGR of 5.5% from 2017-2022.
Industry Growth Insights published a new data on “Cardiac Biomarkers Market”. The research report is titled “Cardiac Biomarkers Market research by Types (Troponin, CK-MB, Natriuretic Peptides - BNP and NT-proBNP, Myoglobin, Others), By Applications (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), By Players/Companies Abbott, Alere, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMérieux, Bio-Rad Laboratories, BODITECH MED”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cardiac Biomarkers Market Research Report
By Type
Troponin, CK-MB, Natriuretic Peptides - BNP and NT-proBNP, Myoglobin, Others
By Application
Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others
By Companies
Abbott, Alere, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMérieux, Bio-Rad Laboratories, BODITECH MED
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Cardiac Biomarkers Market Report Segments:
The global Cardiac Biomarkers market is segmented on the basis of:
Types
Troponin, CK-MB, Natriuretic Peptides - BNP and NT-proBNP, Myoglobin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Alere
- F. Hoffmann-La Roche
- Advanced ImmunoChemical
- AgPlus Diagnostics
- BG Medicine
- BioLegend
- bioMérieux
- Bio-Rad Laboratories
- BODITECH MED
Highlights of The Cardiac Biomarkers Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Troponin
- CK-MB
- Natriuretic Peptides - BNP and NT-proBNP
- Myoglobin
- Others
- By Application:
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cardiac Biomarkers Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cardiac biomarkers are biological markers that can be used to diagnose and monitor heart disease.
Some of the major players in the cardiac biomarkers market are Abbott, Alere, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMƒÂ©rieux, Bio-Rad Laboratories, BODITECH MED.
The cardiac biomarkers market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiac Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cardiac Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cardiac Biomarkers Market - Supply Chain
4.5. Global Cardiac Biomarkers Market Forecast
4.5.1. Cardiac Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cardiac Biomarkers Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cardiac Biomarkers Market Absolute $ Opportunity
5. Global Cardiac Biomarkers Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cardiac Biomarkers Market Size and Volume Forecast by Type
5.3.1. Troponin
5.3.2. CK-MB
5.3.3. Natriuretic Peptides - BNP and NT-proBNP
5.3.4. Myoglobin
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cardiac Biomarkers Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cardiac Biomarkers Market Size and Volume Forecast by Application
6.3.1. Acute Coronary Syndrome
6.3.2. Myocardial Infarction
6.3.3. Congestive Heart Failure
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cardiac Biomarkers Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cardiac Biomarkers Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cardiac Biomarkers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cardiac Biomarkers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cardiac Biomarkers Demand Share Forecast, 2019-2029
9. North America Cardiac Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cardiac Biomarkers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cardiac Biomarkers Market Size and Volume Forecast by Application
9.4.1. Acute Coronary Syndrome
9.4.2. Myocardial Infarction
9.4.3. Congestive Heart Failure
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cardiac Biomarkers Market Size and Volume Forecast by Type
9.7.1. Troponin
9.7.2. CK-MB
9.7.3. Natriuretic Peptides - BNP and NT-proBNP
9.7.4. Myoglobin
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cardiac Biomarkers Demand Share Forecast, 2019-2029
10. Latin America Cardiac Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Application
10.4.1. Acute Coronary Syndrome
10.4.2. Myocardial Infarction
10.4.3. Congestive Heart Failure
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Type
10.7.1. Troponin
10.7.2. CK-MB
10.7.3. Natriuretic Peptides - BNP and NT-proBNP
10.7.4. Myoglobin
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cardiac Biomarkers Demand Share Forecast, 2019-2029
11. Europe Cardiac Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cardiac Biomarkers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cardiac Biomarkers Market Size and Volume Forecast by Application
11.4.1. Acute Coronary Syndrome
11.4.2. Myocardial Infarction
11.4.3. Congestive Heart Failure
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cardiac Biomarkers Market Size and Volume Forecast by Type
11.7.1. Troponin
11.7.2. CK-MB
11.7.3. Natriuretic Peptides - BNP and NT-proBNP
11.7.4. Myoglobin
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cardiac Biomarkers Demand Share, 2019-2029
12. Asia Pacific Cardiac Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Application
12.4.1. Acute Coronary Syndrome
12.4.2. Myocardial Infarction
12.4.3. Congestive Heart Failure
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Type
12.7.1. Troponin
12.7.2. CK-MB
12.7.3. Natriuretic Peptides - BNP and NT-proBNP
12.7.4. Myoglobin
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cardiac Biomarkers Demand Share, 2019-2029
13. Middle East & Africa Cardiac Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Application
13.4.1. Acute Coronary Syndrome
13.4.2. Myocardial Infarction
13.4.3. Congestive Heart Failure
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Type
13.7.1. Troponin
13.7.2. CK-MB
13.7.3. Natriuretic Peptides - BNP and NT-proBNP
13.7.4. Myoglobin
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cardiac Biomarkers Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Cardiac Biomarkers Market: Market Share Analysis
14.2. Cardiac Biomarkers Distributors and Customers
14.3. Cardiac Biomarkers Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Alere
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Advanced ImmunoChemical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AgPlus Diagnostics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BG Medicine
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. BioLegend
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. bioMérieux
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bio-Rad Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BODITECH MED
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook